Pipeline Overview

Armata’s therapeutic phage candidates aim to address areas of significant unmet clinical need, by targeting key antibiotic-resistant bacteria including those on the World Health Organization’s global priority pathogens list. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent are being developed in partnership with Merck. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing.

Program	Discovery	Preclinical	IND-Enabling	Phase 1b/2	Partner
Pseudomonas aeruginosa
Respiratory Infections
AP-PA02	CF
	AP-PA02	NCFB
AP-PA03	Pneumonia
Staphylococcus aureus
AP-SA02	Bacteremia				US DoD*
	Bacteremia	PJI

Phage Candidate	Program	Phase	Partner
AP-PA02	CF Phase 1b/2 NCFB IND-Enabling
AP-PA03	Pneumonia IND-Enabling
AP-SA02	Bacteremia IND-Enabling US DoD* PJI IND-Enabling

CF: cystic fibrosis; NCFB: non-CF bronchiectasis; PJI: prosthetic joint infection
SWARM-P.a. NCT Number; NCT04596319; Cystic Fibrosis Foundation TrialFinder
^*Department of Defense (Naval Medical Research Center, US Army Medical Research Acquisition Activity, Defense Health Agency)

Discovery-Stage
Engineered Phage undisclosed target/indication
Escherichia coli Klebsiella pneumoniae

Discovery-Stage
Engineered Phage undisclosed target/indication
Escherichia coli Klebsiella pneumoniae